Recent Finacing
Recent Raise
Incysus develops off-the-shelf, gene‑modified gamma‑delta T cell therapies and an adoptive-cell platform engineered for chemotherapy resistance to treat hematologic and solid tumors, including leukemia, lymphoma, and glioblastoma.
